Roivant rises after long-term data for ulcerative colitis candidate

Roivant Sciences (NASDAQ:ROIV) added ~12% pre-market Thursday after the U.K.-based biotech announced long-term data from a Phase 2b trial for its once-monthly subcutaneous therapy, RVT-3101, targeted at ulcerative colitis.